



This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: <https://creativecommons.org/licenses/by/4.0/> which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2026

Diabetic ketoacidosis in a thalassemia major patient with secondary hemochromatosis

Akhtar Ali¹, Muneeb Ur Rehman², Waseem Ullah^{2*}, Sami Ullah³

ABSTRACT

Background: Diabetic ketoacidosis (DKA) is a life-threatening acute hyperglycemic complication of diabetes mellitus (DM). Thalassemia major predisposes to DM due to pancreatic dysfunction from iron overload, yet DKA is uncommon in these patients.

Case Presentation: We report a case of an 18-year-old female with thalassemia major and secondary hemochromatosis who presented with acute shortness of breath, drowsiness, and confusion following one day of diarrhea. On examination, she was profoundly hypotensive (BP 54/21 mmHg), tachycardic (PR 131 bpm), hypoxic (SpO₂ 89%), and exhibited acidotic breathing, pallor, bronze skin pigmentation, and cold extremities. Laboratory evaluation revealed severe anemia, marked leukocytosis (>30,000/mm³), metabolic acidosis with hypokalemia, hyperglycemia, and markedly elevated ferritin (>1650 ng/l). The patient was treated with insulin infusion, electrolyte correction, blood transfusion, iron chelation therapy, and supportive measures. She improved clinically, achieved metabolic stabilization, and was discharged in stable condition.

Conclusion: This case underscores that thalassemia-related iron overload can precipitate disturbances in glucose metabolism and rarely present with DKA. Continuous monitoring of glycemic status is essential in thalassemia patients, even when baseline glucose levels are normal, to enable early detection and management of acute metabolic complications.

Keywords: Diabetic ketoacidosis, thalassemia major, secondary hemochromatosis, iron chelation therapy.

Received: 11 February 2025

Revised date: 09 April 2025

Accepted: 06 June 2025

Correspondence to: Waseem Ullah

*Postgraduate Resident, Department of Surgical C Ward, Lady Reading Hospital/ Medical Teaching Institute, Peshawar, Pakistan.

Email: wakenkhan21@gmail.com

Full list of author information is available at the end of the article.

Introduction

Thalassemia major is an inherited hemoglobinopathy that necessitates regular blood transfusions, which can lead to iron overload and consequent secondary hemochromatosis. Iron deposition in the pancreas may impair β -cell function, resulting in insulin deficiency and predisposing patients to glucose metabolism disorders, including diabetes mellitus (DM) and impaired glucose tolerance.¹ While diabetes is a recognized complication of thalassemia major, the occurrence of diabetic ketoacidosis (DKA) remains exceptionally rare and is infrequently reported in contemporary literature.²

The progressive decline in pancreatic β -cell function due to chronic iron accumulation is often insidious and asymptomatic until insulin production falls below a critical threshold.³ This presents a clinical challenge, necessitating heightened vigilance among healthcare providers for early recognition of acute metabolic crises such as DKA.

Here, we report the case of a young female with thalassemia major and secondary hemochromatosis who developed DKA. Approval for publishing was obtained from the hospital, and

written informed consent was secured from the patient prior to manuscript preparation. This case underscores the importance of continuous metabolic monitoring and prompt intervention to prevent life-threatening complications in this vulnerable population.

Case Presentation

An 18-year-old female with a known history of thalassemia major presented to the Emergency Department of Lady Reading Hospital Peshawar with an acute onset of shortness of breath, lethargy, and altered sensorium. The patient reported diarrhea for the preceding 24 hours, with no associated vomiting or abdominal pain. Her past medical history revealed no prior diagnosis of DM, and previous HbA1c measurements had consistently remained within the normal range.

On presentation, the patient appeared acutely ill, drowsy, and confused. Vital signs demonstrated profound hypotension (BP 54/21 mmHg), tachycardia (pulse rate 131 beats/min), and oxygen saturation of 89% on room air.

65 Respiratory examination revealed deep and rapid breathing
 66 consistent with Kussmaul respiration, suggestive of metabolic
 67 acidosis.

68 Physical examination showed bronze skin pigmentation,
 69 indicative of chronic iron overload, along with marked
 70 conjunctival pallor consistent with anemia and cold peripheral
 71 extremities. Neurological assessment demonstrated an
 72 altered mental status with a Glasgow Coma Scale score of
 73 13/15.

74 Initial laboratory evaluation revealed severe anemia,
 75 marked leukocytosis ($>30,000/\text{mm}^3$), metabolic acidosis,
 76 hypokalemia, and hyperglycemia, with a random blood
 77 glucose level exceeding the measurable range of the analyzer.
 78 Serum ferritin levels were markedly elevated ($>1,650 \text{ ng/}$
 79 mL), consistent with significant iron overload.

80 Abdominal ultrasonography demonstrated hepatomegaly,
 81 with a liver span measuring approximately 20 cm (Figures
 82 1-3).

83 Further laboratory assessment performed on the second
 84 day of admission revealed an HbA1c level of 5.6% (reference
 85 range: 4.0%-5.6%), indicating the absence of chronic
 86 hyperglycemia. Blood cultures remained negative after 48
 87 hours of incubation, ruling out bacteremia.

88 Based on the clinical presentation and laboratory
 89 findings, the patient was diagnosed with DKA precipitated
 90 by previously undiagnosed DM secondary to iron-induced
 91 pancreatic dysfunction, in the setting of thalassemia major
 92 with secondary hemochromatosis.

93 The patient was admitted to the intensive care unit and
 94 managed according to standard DKA treatment protocols.
 95 Management included:

- 96 • Continuous intravenous insulin infusion to control
 97 hyperglycemia and suppress ketogenesis.
- 98 • Aggressive fluid resuscitation with isotonic saline to correct
 99 dehydration and severe hypotension.
- 100 • Electrolyte correction, particularly intravenous potassium
 101 replacement, to address hypokalemia.
- 102 • Packed red blood cell transfusions to manage severe
 103 anemia.
- 104 • Iron chelation therapy with deferoxamine to reduce
 105 systemic iron burden and prevent further organ damage.
- 106 • Empirical broad-spectrum antibiotics, initiated due to
 107 suspected infection, although subsequent blood cultures
 108 remained negative.

109 During hospitalization, the patient demonstrated
 110 progressive clinical improvement, with normalization of
 111 blood glucose levels, resolution of metabolic acidosis, and
 112 correction of electrolyte abnormalities. Hemodynamic
 113 stability was restored, with improvement in blood pressure
 114 and heart rate.



Figure 1. Abdominal ultrasound showing hepatomegaly
 Abdominal ultrasound demonstrating an enlarged liver measuring
 approximately 20 cm in span. Computed tomography (CT)
 of the abdomen further confirmed hepatosplenomegaly with
 heterogeneous parenchymal texture.

The patient was discharged after 5 days of hospitalization
 in stable condition, with instructions to continue insulin
 therapy and iron chelation treatment, and was scheduled for
 follow-up with endocrinology and hematology services.

Discussion

This case illustrates a rare presentation of DKA in a
 patient with thalassemia major complicated by secondary
 hemochromatosis. Patients with thalassemia major require
 regular blood transfusions, which frequently lead to
 progressive iron overload and deposition in multiple organs,
 including the pancreas.⁴ Iron accumulation within pancreatic
 β -cells results in structural and functional damage, impairing
 insulin synthesis and secretion. Consequently, patients may
 develop abnormalities in glucose metabolism, including
 impaired glucose tolerance and DM.⁵

Excessive iron deposition within pancreatic islet cells
 contributes to cellular injury through oxidative stress-
 mediated mechanisms, which ultimately leads to β -cell
 apoptosis and reduced insulin production.⁶ The development
 of pancreatic dysfunction in thalassemia patients is typically
 gradual and clinically silent, and symptoms often appear only
 after significant β -cell loss has occurred. In the present case,
 the normal HbA1c level indicated the absence of chronic
 hyperglycemia, suggesting an acute deterioration in insulin
 secretion rather than long-standing diabetes.



148 **Figure 2.** Abdominal CT (coronal view) showing
 149 hepatosplenomegaly. Coronal CT image demonstrating
 150 hepatomegaly (liver enlarged to 20 cm) and splenomegaly (spleen
 151 enlarged to 27 cm) with heterogeneous parenchymal appearance.




Figure 3. Abdominal CT (axial view) showing hepatosplenomegaly. Axial CT image illustrating enlargement of both liver and spleen with heterogeneous parenchymal architecture.

The management of DKA requires rapid correction of hyperglycemia, ketosis, dehydration, and electrolyte disturbances.⁸ In patients with thalassemia major, treatment strategies must also address underlying anemia and iron overload. Blood transfusions may be required to correct severe anemia; however, repeated transfusions further contribute to systemic iron accumulation.⁹ Therefore, iron chelation therapy remains a crucial component of long-term management to prevent iron-induced organ damage.

Another critical aspect of DKA management is the monitoring and correction of hypokalemia. Administration of insulin promotes intracellular potassium uptake, which can further lower serum potassium levels and predispose patients to life-threatening cardiac arrhythmias. Consequently, careful monitoring and timely potassium replacement are essential during treatment.

The available literature regarding DKA in patients with thalassemia major and iron overload remains limited. Recent studies emphasize the importance of early detection of abnormalities in glucose metabolism among thalassemia patients.¹⁰ A study published in 2022 reported a higher prevalence of impaired glucose tolerance and DM in individuals with thalassemia major, supporting the recommendation for regular metabolic screening in this population.¹⁰ Nevertheless, reports of acute DKA in this context remain scarce, suggesting that the condition may be under-recognized or under-reported.

The occurrence of DKA in patients with thalassemia-related diabetes is uncommon and may pose diagnostic challenges. DKA is most frequently associated with type 1 DM, although it may also occur in type 2 diabetes during periods of physiological stress.⁷ Various precipitating factors - including infection, dehydration, or metabolic stress - can trigger DKA by increasing insulin requirements and stimulating the release of counter-regulatory hormones. In the present case, the recent history of diarrhea likely resulted in dehydration and electrolyte imbalance, which may have acted as the precipitating factor for DKA.

190 This case highlights the importance of maintaining a high
191 index of clinical suspicion for acute metabolic complications
192 in patients with thalassemia who present with nonspecific
193 symptoms. Routine monitoring of glycemic status, even in
194 patients without previously documented hyperglycemia, is
195 recommended. Early identification and prompt management
196 of metabolic disturbances may help prevent severe
197 complications and improve overall patient outcomes.

198 Conclusion

199 This case highlights the uncommon yet clinically significant
200 occurrence of DKA in a patient with thalassemia major
201 complicated by secondary hemochromatosis. The case
202 underscores the importance of regular monitoring of
203 glucose metabolism in patients with transfusion-dependent
204 thalassemia, even in the presence of previously normal
205 glycemic parameters. Early recognition of metabolic
206 abnormalities and timely, comprehensive management are
207 essential to prevent potentially life-threatening complications
208 and to improve overall clinical outcomes in this high-risk
209 population.

210 Acknowledgement

211 The authors are thankful to the to Head and staff of the Department
212 of Surgery, Lady Reading Hospital/ Medical Teaching Institute,
213 Peshawar, Pakistan for their clinical and administrative support
214 during execution of the study.

215 List of Abbreviations

216 CT	Computed tomography
217 DKA	Diabetic ketoacidosis
218 DM	Diabetes mellitus
219 GCS	Glasgow Coma Scale
220 ICU	Intensive care unit

221 Conflict of interest

222 None to declare.

223 Grant support and financial disclosure

224 None to disclose.

225 Ethical approval

226 The case was approved for publishing by the Head Department of
227 Surgical C Ward, Lady Reading Hospital/ Medical Teaching Institute,
228 Peshawar, Pakistan.

229 Author's contributions

230 **AA, MUR, WU:** Conception and design of study, acquisition of data,
231 manuscript drafting with critical intellectual input.

232 **SU:** Acquisition of data, manuscript drafting with critical intellectual
233 input.

234 **ALL AUTHORS:** Approval and full responsibility of the final version
235 of the manuscript to be published.

Authors' Details

Akhtar Ali ¹ , Muneeb Ur Rehman ² , Waseem Ullah ² , Sami Ullah ³	236
1. Postgraduate Resident, Department of Emergency Medicine, Lady Reading Hospital/ Medical Teaching Institute, Peshawar, Pakistan	237 238 239 240
2. Postgraduate Resident, Department of Surgical C Ward, Lady Reading Hospital/ Medical Teaching Institute, Peshawar, Pakistan	241 242
3. Postgraduate Resident, Department of Pediatrics, Lady Reading Hospital/ Medical Teaching Institute, Peshawar, Pakistan	243 244

References

- 245 1. Deng L, Mo MQ, Zhong J, Li Z, Li G, Liang Y. Iron overload
246 induces islet β cell ferroptosis by activating ASK1/P-38/
247 CHOP signaling pathway. *PeerJ*. 2023;11:e15206. [https://doi.
248 org/10.7717/peerj.15206](https://doi.org/10.7717/peerj.15206)
249
- 250 2. Mulyadi CK, Effendi B, Pratomo R, Kesuma P, Tahapary DL.
251 Diabetic ketoacidosis presenting in major thalassemia with
252 pancreatic hemosiderosis: a case report. *J Endocr Soc*.
253 2021;5(Suppl_1):A376. [https://doi.org/10.1210/jendso/
254 bvab048.766](https://doi.org/10.1210/jendso/
254 bvab048.766)
- 255 3. Kulvinder K, Kochar K, Kaur K. Association of iron metabolism
256 abnormalities as an etiopathogenetic factor in alteration
257 of beta-cell function and impairment in the generation
258 of diabetes mellitus: a systematic review. *J Clin Res Rep*.
259 2022;11(1):1–13. <https://doi.org/10.31579/2690-1919/241>
260
- 261 4. Taneera J, Mahgoub E, Qannita R, Alalami A, Shehadat OA,
262 Youssef M, et al. β -thalassemia and diabetes mellitus: current
263 state and future directions. *Horm Metab Res*. 2024;56(4):272–
264 8. doi:10.1055/a-2185-5073
- 265 5. Mahgoub EO, Qannita R, Alalami A, Al Shehadat O, Al
266 Mahmoud R, Dib A, et al. Diabetes mellitus progression in
267 β -thalassaemia major patients: the impact of iron overload.
268 *Adv Biomed Health Sci*. 2024;3(1):5–12. doi:10.4103/abhs.
269 abhs_39_23
- 270 6. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A.
271 Challenges of blood transfusions in B-thalassemia.
272 *Blood Rev*. 2019;37:100588. [https://doi.org/10.1016/
273 j.blre.2019.100588](https://doi.org/10.1016/
273 j.blre.2019.100588)
- 274 7. Hesketh C, Lau S, Holloway E. Extreme hypernatraemia and
275 rhabdomyolysis in a child with hyperosmolar hyperglycaemic
276 state mixed with diabeic ketoacidosis. *Practical Diabetes*.
277 2023;40:24–7. <https://doi.org/10.1002/pdi.2484>
278
- 279 8. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM,
280 Brummer D, et al. Diabetes care in the hospital: standards
281 of care in diabetes-2023. *Diabetes Care*. 2023;46(Suppl
282 1):S267–78. doi:10.2337/dc23-S016
- 283 9. Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm
284 shift on beta-thalassaemia treatment: how will we manage this
285 old disease with new therapies? *Blood Rev*. 2018;32(4):300–
286 11. <https://doi.org/10.1016/j.blre.2018.02.001>
287
- 288 10. De Sanctis V, Daar S, Soliman AT, Tzoulis P, Karimi M, Di Maio
289 S, et al. Screening for glucose dysregulation in β -thalassemia
290 major (β -TM): an update of current evidences and personal
291 experience. *Acta Biomed*. 2022;93(1):e2022158. [https://doi.
293 org/10.23750/abm.v93i1.12802](https://doi.
292 org/10.23750/abm.v93i1.12802)